SweetDeep

Indication

Wearable-AI diabetes risk screening

Data source

Multi-sensor wearables (ECG, PPG, BP, BIA, SpO2, skin temperature, motion, activity, sleep) + lifestyle questionnaire

Collaborators

Samsung, AP-HP (Paris), CHSF (Centre Hospitalier Sud Francilien), Hackensack Meridian Health, Jersey Shore University Medical Center, CIC Clinical Research Center & Burjeel Hospitals Network (MENA), Princeton University

Partnership availability

Ready for strategic pilots and commercial discussions — wellness launch path with Samsung; clinical expansion path with pharma/medical device partners

The problem

More than 1.3 billion adults worldwide are metabolically unhealthy — and roughly half are unaware of their risk. Metabolic disease progresses silently: from glucose dysregulation through insulin resistance and vascular damage to organ damage and chronic disease, with symptoms typically surfacing only after irreversible harm has begun. The cost is not silent: US diabetes spending is projected to reach $662 billion annually by 2030. Screening today depends on blood tests and clinic visits — barriers that fall hardest on the populations at greatest risk.

How SweetDeep™ works

SweetDeep™ is the first commercial application of NeuTigers' Wearable-AI™ metabolic intelligence: non-invasive, on-device AI that delivers clinically validated risk insights — anytime, anywhere. It starts from the multi-sensor signals a modern smartwatch already captures:

• ECG
• PPG
• Blood pressure
• BIA
• SpO₂
• Skin temperature
• Motion
• Activity
• Sleep
• Lifestyle questionnaire

1. On-device AI engine

   Proprietary edge-optimized deep-learning algorithms, built on the StarDeep platform.

2. Digital biomarkers

   Physiological sensor signals transformed into metabolic insights.

3. Risk prediction

   AI predicts metabolic disease risk with robust accuracy, specificity and sensitivity.

4. Personalized insights

   Actionable insights that drive behavior change.

5. Early action & prevention

   Early intervention reduces metabolic disease risk and healthcare costs.

Clinical validation

In clinical evaluation, SweetDeep outperforms standard questionnaire-based risk screening (FINDRISC) with a stronger balance of sensitivity and specificity. By combining wearable physiology with AI, it identifies at-risk individuals earlier and enables more efficient referral to confirmatory laboratory testing.

Validation spans 4 prospective clinical studies across 3 continents (US, EU and MENA), conducted with hospital and clinical-research partners including AP-HP (Paris), CHSF, Hackensack Meridian Health, Jersey Shore University Medical Center, and the CIC Clinical Research Center & Burjeel Hospitals Network.

Daily experience

SweetDeep works in free-living conditions, day after day: the watch collects sensor data as users go about their lives, applies on-device data quality control and edge-AI inference, and delivers insights at the point of use. Personal recommendations based on each individual's patterns and trends drive engagement and behavior change — the lever that actually lowers type 2 diabetes risk.

Current status

A proof-of-concept with Samsung on the Galaxy Watch has been successfully completed, and SweetDeep prototype apps are available on Android and Wear OS. The program is ready for strategic pilots and commercial discussions with partners. This status describes the program's evidence and product stage; it does not imply regulatory clearance, approval or diagnostic status in any jurisdiction.

• On-device & private

  Data stays on your device. Privacy by design.

• Edge-AI powered

  Optimized for wearable performance and efficiency.

• Clinically relevant

  Turns everyday data into meaningful health insights.

• Scalable impact

  Affordable, accessible, and built for global reach.

• Better outcomes

  Early insights. Healthier lives. Lower healthcare costs.

Better insight. Better decisions. Better outcomes.

Empowering people to take control of their health.

Collaboration need

We are ready to engage in strategic pilots and commercial discussions — with wellness and device partners on the near-term launch path, and with pharma and medical-device partners on clinical expansion. Partner with us.

Evidence

• SweetDeep — real-time type 2 diabetes detection with a smartwatch (arXiv, 2026) — Data collected in real-world conditions in a decentralized clinical trial with AP-HP.
• Clinical validation across 4 studies on 3 continents (US/EU/MENA)
• Samsung Galaxy Watch proof-of-concept completed; prototype apps on Android and Wear OS

Program status reflects the stage stated above; it does not imply regulatory clearance, diagnostic availability, or commercial deployment unless explicitly stated.

Discuss this program with us →

← All health programs